DXG and its prodrug DAPD have been demonstrated to be effective inhibitors
of HIV-1 in various cells. The EC(50)s for DXG were 0.032 mu M in CBMCs and
0.05 mu M in MT-4 cells, which were generally equipotent as 3TC. 3TC-resis
tant, but not AZT-resistant, HIV-1 had minimum diminished sensitivity to th
e compounds. Both DXG and DAPD were non-toxic to cells up to 500 mu M.